Social media

One billion people worldwide will be living with obesity by 2030. Connect with us at Obesity Week, booth #520 on Nov 4–7 to learn how ICON supports obesity trials with market intelligence, regulatory expertise, and ready...

Meet ICON at #ObesityWeek, Nov 4–7 at booth \#520 to arrange time with our experts and explore how we support next-gen obesity trials. From proof of concept to large portfolios, ICON delivers market intelligence and read...

ICON invites you to attend a presentation by Arjen Akkerman, Senior Director, Accelerated Pharmaceutical Solutions on 28 October at 11:35 am at Messe Frankfurt. In his session, “From collaboration to commitment: Strengt...

ICON invites you to attend a presentation by Arjen Akkerman, Senior Director, Accelerated Pharmaceutical Solutions on 28 October at 11:35 am at Messe Frankfurt. In his session, “From collaboration to commitment: Strengt...

This October, ICON will be in Copenhagen as a proud sponsor of the #OCTNordics conference, taking place on the 21st and 22nd. We invite you to stop by booth #41 to meet our team and discover how ICON is partnering with ...

This October, ICON will be in Copenhagen as a proud sponsor of the #OCTNordics conference, taking place on the 21st and 22nd. We invite you to stop by booth \#41 to meet our team and discover how ICON is partnering with...

Meet ICON’s experts at #ESMO25, booth #3034 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https:...

Meet ICON’s experts at #ESMO25, booth \#3034 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https...

In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...

In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...

In today’s data-rich healthcare landscape, life sciences leaders no longer need to choose between open or closed claims. Integration is the key to unlocking complete, representative, and actionable insights across payer,...

Nearly 30% of the world’s data comes from healthcare—and for life sciences companies, that’s a huge opportunity. But to unlock its full potential, integration is key. Symphony Health, an ICON plc company, is leading the...